Condition

Methotrexate

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 3 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting1

Common interventions3

Lead sponsors shown3

Clinical trials

3 shown

Efficacy and Safety of Resveratrol in Patients With Rheumatoid Arthritis.NCT07089381 · 2025-08-01

RECRUITING

2-week dc of MTX and Influenza Vaccination in RANCT02897011 · 2016-09-01

UNKNOWN

Evaluation of the Impact of 3 Methods of Communication on the Adherence of Methotrexate in Patients With Rheumatoid ArthritisNCT03107299 · 2016-07-05

COMPLETED

Common interventions

MethotrexateDRUG2 Communication methods to encourage adherenceOTHER1 Resveratrol 1 gm.DIETARY_SUPPLEMENT1

Leading sponsors

Ain Shams University 1 Centre Hospitalier Universitaire, Amiens 1 Seoul National University Hospital 1

Trial status mix

COMPLETED1

RECRUITING1

UNKNOWN1

Phase mix

NA3

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.